EMA consults on first qualification opinion on a clinical biomarker
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has for put out for public consultation its first "qualification opinion" on a biomarker for use in humans, and whether two cerebral spinal-fluid related biomarkers are qualified in selecting subjects for trials in early Alzheimer's disease.